retatrutide phase 3 trials Today, we shared new data from two of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide for weight loss: Study

2025;8(3):e250802

But I kept coming back to the safety numbers too, because I am not someone who takes risks lightly

Others reach the highest available dose and still feel uncomfortably hungry

In Mar26, BMS Sotyktu (Deucravacitinib) wins FDA approval to treat adults with active psoriatic arthritis (PsA) Total Revenue: $48.67B Founded Year: 1923 Total Employees: 69,200 Headquarters: Bagsvaerd, Denmark Market Cap: $127.23B Stock Exchange: CPH Novo Nordisk is a global healthcare company focused on diabetes, obesity, and rare diseases, with a strong leadership position in metabolic disorders driven by its GLP-1based therapies and innovation-led pipeline

The Journal of pharmacology and experimental therapeutics